ZipPrime and Lanmer Announce Product Commercialisation Agreement to Distribute ZipPrime’s SARS-CoV-2 Sampling and Detection Products and Lanmer’s PPE Supplies

Press Release : July 07, 2020
ZipPrime and Lanmer Announce Product Commercialisation Agreement to Distribute ZipPrime’s SARS-CoV-2 Sampling and Detection Products and Lanmer’s PPE Supplies

Tartu, Estonia, 07 July 2020, ZipPrime OÜ and Lanmer OÜ, both privately-held Tartu, Estonia-based companies focused on in vitro diagnostics and medical and research solutions, today announced that they have entered into a product commercialisation agreement.

Under the agreement, Lanmer will distribute ZipPrime’s SARS-CoV-2 compatible Viral Sample Transport Solution, Viral Nucleic Acid Isolation Kit, Quick Extraction Kit and RT-PCR SARS-CoV-2 Detection Kit in Europe, with a focus on the Baltic States. In addition, the companies will collaborate in the worldwide distribution of PPE and other COVID-19 relevant solutions sourced by Lanmer.

ZipPrime’s Viral Sample Transport Solution is available in both bulk and collection kit formats (with optional swab) and already has customers worldwide, via ZipPrime OÜ’s Turkish partner company Zip Prime Biyoteknoloji LTD. ŞTİ. (“ZipPrime Turkey”) – its developer and manufacturer. ZipPrime Turkey has additionally developed a Viral Nucleic Acid Isolation Kit, Quick Extraction Kit and RT-PCR SARS-CoV-2 Detection Kit which will also be distributed under the agreement. ZipPrime’s SARS-CoV-2 sampling and detection products offer equal or superior performance relative to the leading products on the market with competitive pricing.

Lanmer is capable of sourcing regulatory-approved Personal Protection Equipment and other COVID-19 related medical and research solutions with short lead and delivery times, for delivery worldwide, including products otherwise hard to obtain.

About ZipPrime OÜ:
Founded in 2013 and incorporated in Estonia in 2019, ZipPrime OÜ, together with partner company ZipPrime Turkey, founded 2008, develops and markets in vitro diagnostic and next-generation sequencing related technologies. ZipPrime has recently applied its DNA & RNA sample-handing know-how and technologies from the cancer liquid biopsy sector to the current COVID-19 pandemic to develop a range of superior products for SARS-CoV-2 sampling and detection. For more information about the company and its products and technology visit www.zipprime.com 

About Lanmer OÜ:
Founded in 2014, Lanmer OÜ offers medical and research solutions and clinical research monitoring services to clients in the Baltics and Nordics. For more information about the company and its products and technology visit www.lanmer.eu/en 

Notes to editors

For more information please contact:
Please direct PPE enquires to Kent Langel: kent.langel@lanmer.eu and SARS-CoV-2 sampling and detection product enquires to Neil Thomas: neil.thomas@zipprime.com Tel: email: neil.thomas@zipprime.com Visit the newsroom of: sampr